What do systematic reviews say?

CHOLINERGIC DRUGS vs placebo

It is very uncertain whether CHOLINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).

• Cholinergic medication for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 1.09 [0.56, 2.1]
  12 studies · 288 participants
  Very low

Switch to another antipsychotic vs antipsychotic cessation

It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).

• Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 0.6 [0.16, 2.25]
  1 study · 50 participants
  Very low

Switch to a specific antipsychotic vs switch to a different specific antipsychotic

• Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 466 participants
  Very low

Specific antipsychotic vs other drugs

It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).

• Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 4.38 [0.25, 76.54]
  1 study · 13 participants
  Very low

Reduced dose of antipsychotics vs antipsychotic maintenance

It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).

• Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 0.33 [0.06, 1.99]
  1 study · 8 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes acceptability of treatment: Leaving the study early (very low certainty).

• Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 1.47 [0.69, 3.15]
  6 studies · 218 participants
  Very low

POLYPEPTIDE ‐ CERULETIDE vs placebo

It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

• Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 1.09 [0.49, 2.4]
  1 study · 85 participants
  Very low

Levetiracetam vs placebo

It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

• Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 1.01 [0.46, 2.22]
  2 studies · 119 participants
  Very low

Vitamin E vs placebo

It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

• Vitamin E for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 1.07 [0.64, 1.8]
  8 studies · 232 participants
  Very low

Benzodiazepines vs phenobarbital (as active placebo)

• Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

Benzodiazepines vs placebo

It is very uncertain whether benzodiazepines changes acceptability of the treatment (measured by participants leaving the… compared with placebo (very low certainty).

• Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 2.73 [0.15, 48.04]
  3 studies · 56 participants
  Very low